FDA Approves Dupixent for Treating Chronic Rhinosinusitis With Nasal Polyposis
The FDA approved Sanofi and Regeneron’s Dupixent (dupilumab) for use with other medications in treating chronic rhinosinusitis with nasal polyposis.
The biologic is the first to be approved for the condition, a subgroup of chronic rhinosinusitis characterized by fleshy swellings in the nasal lining and paranasal sinuses. It is frequently accompanied by other conditions like severe asthma.
The approval is the drug’s third; the FDA previously approved the treatment for moderate-to-severe atopic dermatitis and moderate-to-severe asthma.